【摘要】 目的探讨帕罗西汀联合度洛西汀治疗抑郁伴躯体化障碍患者的疗效。方法采用症状自评量表(SCL-90)和Zung抑郁自评量表(SDS)筛选出抑郁伴躯体化障碍的患者30例,随机分为治疗组和对照组,每组各15例,分别给予口服帕罗西汀+度洛西汀和口服度洛西汀治疗,4周为一个疗程。在治疗前及治疗4周末测量患者的SCL-9和SDS评分。结果 (1)治疗前,两组的SCL-9和SDS评分无明显差异(P>0.05);(2)治疗4周后,治疗组的SDS评分低于对照组,差异有统计学意义(P<0.05);治疗组经过治疗后的SDS评分低于治疗前,差异有统计学意义(P<0.05);(3)治疗4周后,治疗组的SCL-9评分低于对照组,差异有统计学意义(P<0.05);两组在治疗4周后SCL-9评分均低于治疗前,差异有统计学意义(P<0.05)。结论帕罗西汀联合度洛西汀可改善抑郁伴躯体化障碍,值得在临床推广应用。更多还原

【Abstract】 Objective To investigate the clinical efficacy of paroxetine combined with duloxetine in the treatment of depression patients with somatization disorder. Methods Thirty depression patients with somatosensory disorder were enrolled and randomly divided into treatment group(n = 15)and control group(n = 15),given oral paroxetine + duloxetine and oral duloxetine treatment respectively. The duration of treatment was 4 weeks. The SCL-9 and Zung Depression Self-Rating Scale(SDS)were used in all subjects before and after 4 weeks of treatment. Results There was no significant difference in scores of SCL-9 and SDS between the two groups before treatment(P> 0.05).(2) After 4weeks of treatment,the SDS scores in the treatment group were lower than those in the control group(P<0.05).(3)After treatment for 4 weeks,the SCL-9 score of the treatment group was lower than that of the control group,the difference was statistically significant(P<0.05),and the difference was statistically significant(P<0.05). The scores of SCL-9 in the two groups were lower than those before treatment(P<0.05). Conclusion Paroxetine combined with duloxetine can improve the patients’ depression and somatization symptoms.更多还原